Oprozomib in patients with newly diagnosed multiple myeloma.
作者信息
Hari Parameswaran, Matous Jeffrey V, Voorhees Peter M, Shain Kenneth H, Obreja Mihaela, Frye John, Fujii Hisaki, Jakubowiak Andrzej J, Rossi Davide, Sonneveld Pieter
机构信息
Medical College of Wisconsin, Milwaukee, WI, USA.
Colorado Blood Cancer Institute, Denver, CO, USA.
出版信息
Blood Cancer J. 2019 Aug 16;9(9):66. doi: 10.1038/s41408-019-0232-6.
Abstract
摘要
相似文献
1
Oprozomib in patients with newly diagnosed multiple myeloma.奥布佐米布用于新诊断的多发性骨髓瘤患者。
Blood Cancer J. 2019 Aug 16;9(9):66. doi: 10.1038/s41408-019-0232-6.
2
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.奥泼佐米治疗晚期多发性骨髓瘤和华氏巨球蛋白血症的 Ib/II 期研究。
Clin Cancer Res. 2019 Aug 15;25(16):4907-4916. doi: 10.1158/1078-0432.CCR-18-3728. Epub 2019 May 29.
3
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.卡非佐米、来那度胺与低剂量地塞米松用于老年新诊断多发性骨髓瘤患者的治疗
Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27.
4
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.对于新诊断的多发性骨髓瘤患者，自体造血干细胞移植（ASCT）后使用卡非佐米、来那度胺和地塞米松（KRd）进行巩固治疗可导致高比例的微小残留病阴性，并在不使用双膦酸盐的情况下改善骨代谢。
Blood Cancer J. 2020 Mar 2;10(3):25. doi: 10.1038/s41408-020-0297-2.
5
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.达雷妥尤单抗和卡非佐米对新诊断的间变性多发性骨髓瘤疗效不佳。
J Clin Exp Hematop. 2020;60(1):17-20. doi: 10.3960/jslrt.19031.
6
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.奥泊佐米、泊马度胺和地塞米松治疗复发和/或难治性多发性骨髓瘤患者。
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):570-578.e1. doi: 10.1016/j.clml.2019.05.017. Epub 2019 May 29.
7
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.奥普佐米与地塞米松治疗复发和/或难治性多发性骨髓瘤患者的 1b/2 期、多中心、开放标签研究的疗效和安全性结果。
Leuk Res. 2019 Aug;83:106172. doi: 10.1016/j.leukres.2019.106172. Epub 2019 Jun 17.
8
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.卡非佐米用于新诊断的不适合移植的多发性骨髓瘤的维持治疗。
Leukemia. 2022 Mar;36(3):881-884. doi: 10.1038/s41375-021-01415-x. Epub 2021 Oct 14.
9
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.卡非佐米、维奈克拉和地塞米松用于复发/难治性多发性骨髓瘤
Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.
10
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
引用本文的文献
1
Marizomib in the therapy of brain tumors-how far did we go and where do we stand?马立佐米在脑肿瘤治疗中的应用——我们进展如何，现状如何？
Pharmacol Rep. 2025 May 29. doi: 10.1007/s43440-025-00739-0.
2
Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment.抗癌药物的心脏毒性：分子机制、临床管理和创新治疗。
Drug Des Devel Ther. 2024 Sep 12;18:4089-4116. doi: 10.2147/DDDT.S469331. eCollection 2024.
3
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.《NF-κB药典：制服顽固靶点的新策略》
Biomedicines. 2022 Sep 8;10(9):2233. doi: 10.3390/biomedicines10092233.
4
Multiple Myeloma Therapy: Emerging Trends and Challenges.多发性骨髓瘤治疗：新趋势与挑战
Cancers (Basel). 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082.
5
Pathogenesis and treatment of multiple myeloma.多发性骨髓瘤的发病机制与治疗
MedComm (2020). 2022 Jun 2;3(2):e146. doi: 10.1002/mco2.146. eCollection 2022 Jun.
6
Importance of Deubiquitination in Macrophage-Mediated Viral Response and Inflammation.去泛素化在巨噬细胞介导的病毒反应和炎症中的重要性。
Int J Mol Sci. 2020 Oct 29;21(21):8090. doi: 10.3390/ijms21218090.
7
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.去泛素化酶抑制作用的进展及其在癌症治疗中的应用
Cancers (Basel). 2020 Jun 15;12(6):1579. doi: 10.3390/cancers12061579.
8
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.蛋白酶体作为一个具有多种治疗潜力的可药物靶标：有切与非切的两面性。
Pharmacol Ther. 2020 Sep;213:107579. doi: 10.1016/j.pharmthera.2020.107579. Epub 2020 May 19.
9
The role of ubiquitination in tumorigenesis and targeted drug discovery.泛素化在肿瘤发生和靶向药物发现中的作用。
Signal Transduct Target Ther. 2020 Feb 29;5(1):11. doi: 10.1038/s41392-020-0107-0.
10
Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.靶向泛素-蛋白酶体系统（UPS）治疗人类癌症的药物研发
Cancers (Basel). 2020 Apr 7;12(4):902. doi: 10.3390/cancers12040902.
本文引用的文献
1
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).一项关于卡非佐米、环磷酰胺和地塞米松用于新诊断的多发性骨髓瘤患者的多中心、开放标签1b期研究（CHAMPION-2）。
Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):433-437. doi: 10.1016/j.clml.2017.05.009. Epub 2017 May 10.
2
Myeloma: management of the newly diagnosed high-risk patient.骨髓瘤：新诊断高危患者的管理
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):485-494. doi: 10.1182/asheducation-2016.1.485.
3
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.卡非佐米、泊马度胺和地塞米松用于复发或难治性骨髓瘤。
Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17.
4
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.来那度胺扩展疗程的卡非佐米-来那度胺-地塞米松治疗冒烟型或新诊断多发性骨髓瘤患者。
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
5
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.卡非佐米、环磷酰胺和地塞米松治疗新诊断多发性骨髓瘤患者的多中心、2 期研究。
Blood. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22.
6
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.一项卡非佐米联合来那度胺和低剂量地塞米松作为多发性骨髓瘤一线治疗的 1/2 期研究。
Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.
7
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.硼替佐米治疗多发性骨髓瘤时的周围神经病：近期研究综述。
Leuk Lymphoma. 2010 Jul;51(7):1178-87. doi: 10.3109/10428194.2010.483303.
8
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).口服生物可利用且具有选择性的肽环氧酮蛋白酶体抑制剂（PR - 047）的设计与合成
J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v.
Zotero 插件